Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, United States of America.
Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, United States of America.
PLoS One. 2022 Feb 14;17(2):e0263573. doi: 10.1371/journal.pone.0263573. eCollection 2022.
Testicular cancer survivors (TCS) have an increased risk of additional cancers, including prostate cancer. Our understanding of the natural history of prostate cancer in testicular cancer survivors is very limited due to its rare incidence.
Using the Surveillance, Epidemiology, and End Results (SEER) Registry from 1978 to 2011, we identified 282 TCS with subsequent prostate cancer and examined the tumor grade and clinical outcomes in contrast to men with primary prostate cancer in the general population.
TCS with a subsequent prostate cancer diagnosis were more likely to be diagnosed at a younger age than men with primary prostate cancer (65.2% vs. 37.6% for age ≤65, 34.8% vs. 62.4% for age >65, p<0.001) and were more likely to have grade III/IV tumors (46.2% vs. 37.0%, p<0.002). Longer latency between testicular and prostate cancer diagnoses was associated with a higher risk of grade III/IV (p<0.001) cancer. Despite the increased risk for high-grade tumors, 10-year prostate cancer-specific survival and overall survival were not significantly different between TCS and men with primary prostate cancer. Based on the available information in SEER, we found that prior history of radiotherapy for testicular cancer had no impact on tumor grade or survival outcomes.
Prostate cancer in TCS was more likely to be diagnosed at a younger age and with higher grades. Risks of grade III/IV disease increased with longer latency between testicular and prostate cancer diagnoses. Radiotherapy for testicular cancer did not appear to have a significant impact on the outcome of subsequent prostate cancer.
睾丸癌幸存者(TCS)发生其他癌症(包括前列腺癌)的风险增加。由于前列腺癌发病率较低,我们对睾丸癌幸存者中前列腺癌的自然史了解非常有限。
我们使用 1978 年至 2011 年的监测、流行病学和最终结果(SEER)登记处,确定了 282 例随后被诊断患有前列腺癌的 TCS,并检查了与一般人群中原发性前列腺癌患者相比的肿瘤分级和临床结局。
与原发性前列腺癌患者相比,诊断为随后发生前列腺癌的 TCS 更有可能在较年轻的年龄被诊断(年龄≤65 岁的患者中为 65.2%比 37.6%,年龄>65 岁的患者中为 34.8%比 62.4%,p<0.001),且更有可能患有 III/IV 级肿瘤(46.2%比 37.0%,p<0.002)。睾丸癌和前列腺癌诊断之间潜伏期较长与 III/IV 级(p<0.001)癌症的风险增加相关。尽管高级别肿瘤的风险增加,但 TCS 和原发性前列腺癌患者的 10 年前列腺癌特异性生存率和总生存率并无显著差异。根据 SEER 中提供的信息,我们发现睾丸癌的放射治疗史对肿瘤分级或生存结局没有影响。
TCS 中的前列腺癌更可能在较年轻时被诊断出,且分级更高。睾丸癌和前列腺癌诊断之间潜伏期较长与 III/IV 级疾病的风险增加相关。睾丸癌的放射治疗似乎对随后发生的前列腺癌的结局没有显著影响。